Bernard emphasized strong performances in the QIAstat Diagnostics and QuantiFERON portfolios, with QIAstat achieving 25% CER growth in Q4 and over 660 new system placements in 2024. QuantiFERON grew ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback